Curis Lifesciences Ltd. IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 1,017,000 (47%) | — | ₹1,302 Cr |
| NII (HNI) | — | 309,000 (14%) | — | ₹396 Cr |
| Retail | — | 716,000 (33%) | — | ₹916 Cr |
| Market Maker | — | 108,000 (5%) | — | ₹14 Cr |
| Σ Total | — | 2,150,000 (100%) | — | ₹27,520 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 1,000 | ₹128,000 |
| Retail (Max) | 13 | 13,000 | ₹1,664,000 |
| S-HNI (Min) | 14 | 14,000 | ₹1,792,000 |
| B-HNI (Min) | 67 | 67,000 | ₹8,576,000 |
Financial Statements Amount in ₹ Crore
| Metric | 31 Jul 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Revenue | 20 | 50 | 36 |
| EBITDA | 4 | 10 | 8 |
| Profit After Tax | 3 | 6 | 5 |
| Net Worth | 19 | 16 | 6 |
| Total Assets | 56 | 43 | 34 |
| Reserves & Surplus | 13 | 10 | 5 |
| Total Borrowing | 15 | 16 | 17 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- 1 Capital Expenditure towards Upgradation/Improvement of the existing Manufacturing Facilities – 2.44
- 2 Capital Expenditure towards Construction of a Storage Facility – 3.62
- 3 Pre-payment/Repayment of outstanding Secured Loans – 1.86
- 4 Product Registrations in other countries – 2.69
- 5 Funding our Working Capital Requirements – 11.25
- 6 General Corporate Purposes –
Company Overview
Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.
The company manufactures pharmaceutical products globally and domestically on a loan license or contract basis, as well as for its own brand marketing.
The company serves over 100 corporate clients on loan licenses or contract manufacturing and 2 clients for its own brand marketing in Yemen and Kenya.
Products:
- General pharmaceutical tablets and capsules
- Oral liquids
- External preparations
- Sterile ophthalmic ointments
The company operates a state-of-the-art manufacturing facility in Sanand, Gujarat, adhering to stringent quality control measures to ensure product safety and efficacy.
As of July 31, 2025, the company has 95 permanent employees.
Competitive Strengths:
- Experienced Promoters and Management Team
- Wide range of Products
- Strategic Location of Manufacturing Facility
- Scalable Business Model
- Quality assurance